BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25349319)

  • 1. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
    Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
    Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Necrotizing Funisitis as an Intrauterine manifestation of Cryopyrin-Associated Periodic Syndrome: a case report and review of the literature.
    Yokoi K; Minamiguchi S; Honda Y; Kobayashi M; Kobayashi S; Nishikomori R
    Pediatr Rheumatol Online J; 2021 May; 19(1):77. PubMed ID: 34059097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
    Russo RA; Melo-Gomes S; Lachmann HJ; Wynne K; Rajput K; Eleftheriou D; Edelsten C; Hawkins PN; Brogan PA
    Rheumatology (Oxford); 2014 Apr; 53(4):665-70. PubMed ID: 24352339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA.
    Goldbach-Mansky R
    Curr Rheumatol Rep; 2011 Apr; 13(2):123-31. PubMed ID: 21538043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cryopyrin-associated periodic syndromes].
    Quartier P; Rodrigues F; Georgin-Lavialle S
    Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
    Kuemmerle-Deschner JB; Hofer F; Endres T; Kortus-Goetze B; Blank N; Weißbarth-Riedel E; Schuetz C; Kallinich T; Krause K; Rietschel C; Horneff G; Benseler SM
    Rheumatology (Oxford); 2016 Apr; 55(4):689-96. PubMed ID: 26667214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cryopyrin-associated periodic syndrome].
    Kümmerle-Deschner JB
    Z Rheumatol; 2012 Apr; 71(3):199-208. PubMed ID: 22527214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal treatment of CINCA syndrome.
    Paccaud Y; Berthet G; Von Scheven-Gête A; Vaudaux B; Mivelaz Y; Hofer M; Roth-Kleiner M
    Pediatr Rheumatol Online J; 2014; 12():52. PubMed ID: 25584041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
    Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
    Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
    Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
    Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review.
    Finetti M; Omenetti A; Federici S; Caorsi R; Gattorno M
    Orphanet J Rare Dis; 2016 Dec; 11(1):167. PubMed ID: 27927236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.
    Aksentijevich I; Nowak M; Mallah M; Chae JJ; Watford WT; Hofmann SR; Stein L; Russo R; Goldsmith D; Dent P; Rosenberg HF; Austin F; Remmers EF; Balow JE; Rosenzweig S; Komarow H; Shoham NG; Wood G; Jones J; Mangra N; Carrero H; Adams BS; Moore TL; Schikler K; Hoffman H; Lovell DJ; Lipnick R; Barron K; O'Shea JJ; Kastner DL; Goldbach-Mansky R
    Arthritis Rheum; 2002 Dec; 46(12):3340-8. PubMed ID: 12483741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
    Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
    Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
    Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
    Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAPS--pathogenesis, presentation and treatment of an autoinflammatory disease.
    Kuemmerle-Deschner JB
    Semin Immunopathol; 2015 Jul; 37(4):377-85. PubMed ID: 25963520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.